NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary Chapter: 8 - Malignant disease and immunosuppression 
Notes:

Any drug not listed on the Formulary should be considered Non-Formulary - Not recommended for prescribing

08.01.05 Other antineoplastic drugs
08.01.05 Amsacrine
08.01.05 Arsenic trioxide
08.01.05 Bevacizumab

Bevacizumab (AvastinĀ®)
(25 mg/ml concentrate for solution for infusion. )

RED
Restricted Drug Restricted

No malignant indications have been approved by NICE.
FOR ALL PRESCRIBING - Blueteq or High Cost drug from requested - see link from Formulary homepage

To be used in accordance with the following NICE TA(s):

MHRA Drug Safety Update (January 2011) - Bevacizumab and sunitinib: risk of osteonecrosis of the jaw NICE TA212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer NICE TA214: Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review) NICE TA263: Breast cancer with capecitabine NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab NICE TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma NICE TA693: Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer NICE TA885: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (replaced by TA939) NICE TA939: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer NICE TA946: Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer NICE TA1008: Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments
08.01.05 Bexarotene
08.01.05 Bortezomib
08.01.05 Brentuximab vedotin
08.01.05 Cetuximab
08.01.05 Crisantaspase
08.01.05 Dacarbazine and Temozolomide
08.01.05 Erlotinib
08.01.05 Hydroxycarbamide
08.01.05 Imatinab
08.01.05 Ipilimumab
08.01.05 Mitotane
08.01.05 Panitumumab
08.01.05 Pentostatin
08.01.05 Platinum compounds
08.01.05 Porfimer sodium and temoporfin
08.01.05 Procarbazine
08.01.05 Protein kinase inhibitors
08.01.05 Taxanes
08.01.05 Topoisomerase I inhibitors
08.01.05 Trabectedin
08.01.05 Trastuzumab
08.01.05 Tretinoin
08.01.05 Vismodegib
Classifications
May be initiated in any care setting
Specialist to advise therapy and provide first 28 days supply, continuation in Primary Care
Specialist to initiate and stabilise medicine prior to continuation in Primary Care
To be prescribed as per Shared Care Guidance. If no SCG in place status reverts to red.
Red medicines are designated as specialist only medicines which should only be prescribed by a specialist, usually within secondary care (either due to the requirement for specialist knowledge, long-term monitoring requirements, or restrictions that mean medicine supplies are only available to hospitals).
A decision has been made either locally and/or nationally not to routinely commission this preparation. Do not prescribe.
To be purchased over the counter. May be prescribed for chronic, long term conditions or on admission to hospital if essential.